MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab Versus Maintenance Avelumab After First Line Platinum-Based Chemotherapy in Patients with Metastatic Urothelial Cancer

August 1, 2022

Protocol: Alliance – A032001

Schema – A032001

Please Note: Below is partial eligibility, for full eligibility requirement’s, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank you!


  1. Histologically or cytologically-confirmed diagnosis of advanced or metastatic urothelial cancer of the renal pelvis, ureter, bladder, or urethra (transitional cell
    and mixed transitional/non-transitional cell histologies except for small-cell histology), including N3 only disease prior to start of first-line platinum-based chemotherapy.
  2. Prior first-line treatment must have consisted of 4-6 cycles of 1st-line therapy (platinum-based chemotherapy; gemcitabine-cisplatin, gemcitabine-carboplatin,
    MVAC or ddMVAC).
  3. No more than 1 line of prior chemotherapy for metastatic or locally advanced disease (neoadjuvant or adjuvant chemotherapy will be allowed if given 12 or more
    months prior to registration).
  4. Tumor objective response of CR, PR, or SD upon completion of first line platinum based chemotherapy.
  5. The last dose of first-line chemotherapy must have been received no less than 3 weeks, and no more than 10 weeks, prior to randomization in the present study.
  6. No prior immunotherapy with IL-2, IFN-α, or an anti-PD-1, anti-PD-L1, anti-PDL2, anti-CD137, or CTLA-4 antibody (including ipilimumab), or any other
    antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.
  7. Age ≥ 18 years.
  8. ECOG Performance Status of 0 or 1.

Genesys Hurley Cancer Institute

302 Kensington Avenue (Print a Map)
Flint, MI 48503

810-762-8226 | 888-762-8675

Ascension Genesys Hospital
Hurley Medical Center
Michigan Cancer Consortium


Ⓒ 2020 Genesys Hurley Cancer Institute | All Rights Reserved.